Market Overview

Goldman Sachs: Odonate Therapeutics Has Potential, But There's Greater Upside Elsewhere

Share:
Goldman Sachs: Odonate Therapeutics Has Potential, But There's Greater Upside Elsewhere
Related
The Week Ahead: Apple's Developer Conference In The Spotlight, ASCO Meeting Could Move Biotechs
41 Biggest Movers From Yesterday
Report: Exploring Fundamental Drivers Behind Infinity Pharmaceuticals, AxoGen, MUELLER WATER ... (GuruFocus)

Odonate Therapeutics Inc (NASDAQ: ODT) is a late-stage biopharmaceutical company focused on the treatment of HER2-/HR+ metastatic breast cancer. Most recently, the company began a Phase 3 study of its tesetaxel therapy Contessa.

The Analyst

Goldman Sachs' Dana Flanders initiated coverage of Odonate's stock with a Neutral rating and $27 price target.

The Thesis

An unmet need exists for improving quality of life for metatastic breast cancer patients and Odonate's tesetaxel successfully showed a differentiated profile in prior Phase 2 studies relative to on-market IV taxanes, Flanders said. (See the analyst's track record here.) 

With an eventual launch of tesetaxel in the U.S. in 2021, followed by a launch in the EU region in 2022 and a 2023 Japanese launch, Odonate could see peak worldwide sales of $1.2 billion, according to Goldman Sachs. 

But Odonate's stock isn't necessarily a buy, and investors may find better value elsewhere, the analyst said. Specifically, Goldman's $27 price target is based on a discounted cash flow model that assumes a 13-percent weighted average cost of capital, a 5-percent terminal growth rate, a ramp in margins in the low 60-percent range and a 20-percent tax rate.

The stock's 8-percent upside potential implies that there is "greater relative upside elsewhere" within Goldman Sach's coverage universe, Flanders said. 

Price Action

Shares of Odonate Therapeutics were down 2.24 percent at $24.44 at the time of publication Tuesday.

Related Links:

The Current State Of The Breast Cancer Treatment Space

Puma Biotechnology Boosted After FDA Approves Breast Cancer Therapy

Latest Ratings for ODT

DateFirmActionFromTo
Jan 2018Goldman SachsInitiates Coverage OnNeutral
Jan 2018Cowen & Co.Initiates Coverage OnOutperform
Jan 2018JefferiesInitiates Coverage OnBuy

View More Analyst Ratings for ODT
View the Latest Analyst Ratings

Posted-In: breast cancer Clinical StageAnalyst Color Health Care Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (ODT)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NKEOppenheimerUpgrades0.0
SBEvercore ISI GroupUpgrades4.5
PTIRBC CapitalUpgrades0.0
GPSJP MorganDowngrades24.0
GIIIB. Riley FBRUpgrades47.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Nordstrom Troubles Are Priced In At This Point; JPMorgan Upgrades Stock

Things Could Get Worse Before They Get Better For Interpublic Group, Macquarie Downgrades